Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 1/20 | 0.51 |
| ▸ | NT5E | P21589 | 3/20 | 0.50 |
| ▸ | CASP6 | P55212 | 4/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.47 |
| ▸ | MPL | P40238 | 3/20 | 0.47 |
| ▸ | NSD2 | O96028 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.43 |
| ▸ | DUSP3 | P51452 | 2/20 | 0.43 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SUMO2 | P61956 | 1/20 | 0.40 |
| ▸ | SUMO1 | P63165 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | SENP2 | Q9HC62 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18274861 | 1.00 | PTGES (0.51) | PTGESNT5ECASP6HSD17B10ALDH1A1 | |
| SCHEMBL29364155 | 0.98 | PTGES (0.52) | PTGESNT5ECASP6HSD17B10ALDH1A1 | |
| SCHEMBL18274862 | 0.98 | PTGES (0.52) | PTGESNT5ECASP6HSD17B10ALDH1A1 | |
| SCHEMBL118229 | 0.98 | PTGES (0.52) | PTGESNT5ECASP6HSD17B10ALDH1A1 | |
| SCHEMBL31255685 | 0.98 | PTGES (0.52) | PTGESNT5ECASP6HSD17B10ALDH1A1 | |
| Sulfuric Acid SCHEMBL8333659 | 0.96 | PTGES (0.51) | PTGESNT5ECASP6HSD17B10ALDH1A1 | |
| SCHEMBL9179236 | 0.96 | PTGES (0.51) | PTGESNT5ECASP6HSD17B10ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL28460415 | 0.96 | PTGES (0.51) | PTGESNT5ECASP6HSD17B10ALDH1A1 | |
| SCHEMBL30687388 | 0.96 | PTGES (0.51) | PTGESNT5ECASP6HSD17B10ALDH1A1 | |
| SCHEMBL5036935 | 0.96 | PTGES (0.51) | PTGESNT5ECASP6HSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11752086-B2 | Topical formulations and methods | MYOCEPT INC. (US) | 2023-09-12 | — | — | US | disclosed |
| CN-111182884-B | Inorganic sunscreen coated with adducts of hydroxycinnamic esters and silanols | 维佐尔有限责任公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-115594987-A | Acid orange disazo dye and preparation method thereof | 金华恒利康化工有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| CN-112341836-B | Weak acid red bisazo dye and preparation method thereof | 金华恒利康化工有限公司 | 2021-09-21 | — | — | CN | disclosed |
| CN-112341836-A | Weak acid red bisazo dye and preparation method thereof | 金华恒利康化工有限公司 | 2021-02-09 | — | — | CN | disclosed |
| CN-110612093-A | Topical formulations and methods | 麦欧赛普特股份有限公司 | 2019-12-24 | — | — | CN | disclosed |
| WO-2018148338-A1 | TOPICAL FORMULATIONS AND METHODS | PETERS LARS ERIK (US) | 2018-08-16 | — | — | WO | disclosed |
| US-20170105967-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF INFLAMMATORY SKIN CONDITIONS USING ALLANTOIN | SCIODERM, INC. (US) | 2017-04-20 | — | — | US | disclosed |
| US-20170105968-A1 | Compositions and Methods for Treatment of Inflammatory Skin Conditions Using Allantoin | SCIODERM, INC. (US) | 2017-04-20 | — | — | US | disclosed |
| US-20170049749-A1 | METHODS FOR TREATING BURNS USING ALLANTOIN | Scioderm.Inc. (US) | 2017-02-23 | — | — | US | disclosed |
| US-20060045926-A1 | Methods and compositions for enhancing collagen and proteoglycan synthesis in the skin | NIMNI MARCEL | 2006-03-02 | — | — | US | disclosed |
| US-20030157137-A1 | Emulsified skin care composition containing salicylic acid, lanolin oil, and propylene glycol | ALWYN COMPANY, INC. | 2003-08-21 | — | — | US | disclosed |
| US-20030147968-A1 | Allantoin-containing preparations for administration as gels and aerosols | ALWYN COMPANY, INC. | 2003-08-07 | — | — | US | disclosed |
| WO-2003053369-A1 | ALLANTOIN-CONTAINING PREPARATIONS FOR ADMINISTRATION AS GELS AND AEROSOLS | ALWYN COMPANY, INC. (US) | 2003-07-03 | — | — | WO | disclosed |
| WO-2003041688-A1 | METHODS FOR TREATMENT OF INFLAMMATORY DISEASES | ALWYN COMPANY, INC. (US) | 2003-05-22 | — | — | WO | disclosed |
| WO-2003041651-A2 | ALLATOIN-CONTAINING SKIN CREAM | ALWYN COMPANY, INC. (US) | 2003-05-22 | — | — | WO | disclosed |
| US-20020054895-A1 | And at least one anionic or nonionic emulsifier that is substantially hydrophilic and is soluble in water; skin protectants | ALWYN COMPANY, INC. | 2002-05-09 | — | — | US | disclosed |
| US-20020055531-A1 | Methods for treatment of inflammatory diseases | SWEEN, MAURICE ALWYN | 2002-05-09 | — | — | US | disclosed |
| US-6376557-B1 | TRANSDERMAL SUPPLYING | ZAVERI CHANDA BHUWALKA (US) | 2002-04-23 | — | — | US | disclosed |
| WO-2001068107-A1 | HAIR RESTORATION FORMULATION | ZAVERI CHANDA BHUWALKA (US) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170049749-A1 | METHODS FOR TREATING BURNS USING ALLANTOIN | ALKBH1, ALKBH3, FAAH2 | PTGES 148/4885NT5E 621/4885CASP6 459/4885 |
| US-20060045926-A1 | Methods and compositions for enhancing collagen and proteoglycan synthesis in the skin | COL1A1, COL14A1, COL2A1 | PTGES 177/4885NT5E 3463/4885CASP6 2567/4885 |
| US-20170105967-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF INFLAMMATORY SKIN CONDITIONS USING ALLANTOIN | CUTA, ITCH, ARG1 | PTGES 180/4885NT5E 4824/4885CASP6 904/4885 |
| US-20170105968-A1 | Compositions and Methods for Treatment of Inflammatory Skin Conditions Using Allantoin | CUTA, ITCH, ARG1 | PTGES 191/4885NT5E 4831/4885CASP6 917/4885 |
| US-11752086-B2 | Topical formulations and methods | KRT18, ANXA3, VIP | PTGES 2463/4885NT5E 2813/4885CASP6 1919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.